Call: 631.543.3334

Gemini Pharmaceuticals Expands Capabilities to Offer Clients Non-GMO Project Verified Products

For Immediate Release

Commack, NY (April 11, 2017) – Gemini Pharmaceuticals, a 30+ year-old contract manufacturer of dietary supplements and OTC pharmaceuticals, announced today it has participated as the Handler in the verification of a client’s product to the standard established by the Non-GMO Project. The certification was provided by NSF International as the Technical Administrator for the Non-GMO Project.

“This is affirmation by the leading organizations that we provide non- GMO products to the market, and verifies that both our supply chain, vendor relations and our internal manufacturing and quality operations can provide repeatable, verifiable products for our customers avoiding GMO’s,” stated Mike Finamore, Chief Executive Officer of Gemini. He added, “This, combined with our other cGMP registrations, gives Gemini client’s assurance that their products are made to the highest industry standards.”

“Verification to the Non-GMO Project standards assures the integrity the product claims,” said Nancy Knight, Business Unit Manager, QAI, Inc, an NSF International organization. “We welcome Gemini Pharmaceutical’s verification to the Non-GMO Project standard, which can provide customers peace of mind knowing the manufacturing, ingredients, and products they produced meet the rigorous verification standards.”

About Gemini Pharmaceuticals:

Gemini Pharmaceuticals Inc, of Commack NY, is a leading contract manufacturer of both dietary supplements and OTC pharmaceuticals. With over 30 years of experience, Gemini is world class manufacturer of solid dosage products with production exceeding 13 billion tablets/ capsules per year. The quality of the operation has been recognized by the achievement of both NSF and TGA registrations and a Health Canada Site Reference Number. Gemini manufactures products in compliance with both Kosher and Halal requirements. For more information, please visit


Media Contact: Mark Jost

Comments are closed.